Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $801.00 at Truist Financial

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target trimmed by Truist Financial from $818.00 to $801.00 in a report published on Tuesday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently weighed in on REGN. Evercore boosted their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research note on Thursday, January 22nd. BMO Capital Markets raised their target price on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. Bank of America upgraded shares of Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and lifted their target price for the stock from $627.00 to $860.00 in a report on Wednesday, January 7th. Guggenheim boosted their target price on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Finally, JPMorgan Chase & Co. upped their price target on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $804.70.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $772.64 on Tuesday. The business’s 50-day simple moving average is $765.77 and its 200-day simple moving average is $710.84. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. Regeneron Pharmaceuticals has a 52 week low of $476.49 and a 52 week high of $821.11. The firm has a market cap of $81.68 billion, a price-to-earnings ratio of 18.59, a P/E/G ratio of 2.01 and a beta of 0.41.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the company earned $12.07 EPS. The company’s revenue for the quarter was up 2.5% on a year-over-year basis. As a group, equities research analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were paid a $0.94 dividend. The ex-dividend date was Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.05%.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 46.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Jason Pitofsky sold 2,036 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the sale, the senior vice president owned 4,272 shares in the company, valued at $3,325,837.44. This represents a 32.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 5,274 shares of company stock worth $4,142,738. 7.02% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Dodge & Cox grew its holdings in shares of Regeneron Pharmaceuticals by 64.6% during the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after purchasing an additional 1,502,198 shares in the last quarter. Norges Bank bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $1,012,296,000. Price T Rowe Associates Inc. MD raised its stake in shares of Regeneron Pharmaceuticals by 142.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock valued at $1,504,991,000 after purchasing an additional 1,144,887 shares in the last quarter. Nuveen LLC lifted its position in Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after purchasing an additional 835,240 shares during the period. Finally, Wellington Management Group LLP lifted its position in Regeneron Pharmaceuticals by 8,620.0% in the fourth quarter. Wellington Management Group LLP now owns 664,465 shares of the biopharmaceutical company’s stock worth $512,881,000 after purchasing an additional 656,845 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Japan approved Dupixent for moderate-to-severe bullous pemphigoid, giving Regeneron (co‑developer of Dupixent) a first targeted approval in a rare skin disease — this expands Dupixent’s labeled indications and potential revenue streams. A Look At Regeneron Pharmaceuticals (REGN) Valuation After Japan’s Approval Of Dupixent For Bullous Pemphigoid
• Positive Sentiment: Piper Sandler initiated coverage with an “overweight” and a $875 price target, signaling institutional bullishness and providing a high-profile positive catalyst for investor sentiment. Regeneron now covered by Piper Sandler
• Positive Sentiment: Broker note coverage and buy-side interest (Seeking Alpha summary of Piper’s overweight) reinforce the upgrade momentum and may drive incremental flows into the stock. Regeneron a new overweight at Piper on Dupixent, pipeline
• Positive Sentiment: Jim Cramer mentioned Regeneron as a notable GLP‑1/weight-loss play, which often fuels retail buying and short‑term volume uplift. Regeneron Pharma (REGN) Shares Up After Jim Cramer Called It a Good Stock
• Positive Sentiment: Regeneron and partner Bayer’s high‑dose aflibercept Phase 3 program in China is approaching a key readout/inflection point for eye‑care growth — a positive potential revenue driver if results support label expansion. High-Dose Aflibercept Trial in China Nears Key Inflection Point
• Neutral Sentiment: Truist lowered its price target slightly (from $818 to $801) but kept a “buy” rating — modestly reduces upside from that shop but leaves institutional endorsement intact. Truist lowers REGN price target
• Neutral Sentiment: Long-form bullish coverage (The Motley Fool) highlights Regeneron’s strengths and long‑term potential but is more thematic and less likely to move the stock near‑term than concrete approvals or readouts. Regeneron: A Strong Contender in the Biotech Arena
• Neutral Sentiment: Broader industry headlines (Bayer Kerendia EU approval, Merck cholesterol data, AstraZeneca COPD wins) illustrate an active competitive/innovation environment; these are worth monitoring but not direct Regeneron-specific negatives today. Bayer Wins EC Approval to Expand Kerendia

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.